Lawsuits Over Ozempic, Other GLP-1 Drugs: Are Label Warnings Adequate?

In recent years, millions of Americans have turned to medications like Ozempic, Wegovy, and Mounjaro, which belong to the class of drugs known as glucagon-like peptide-1 receptor agonists (GLP-1 RA), for weight loss and diabetes management. These drugs have been aggressively promoted by their manufacturers as safe and effective. However, a growing number of former users are now pursuing lawsuits against the manufacturers, alleging that they have suffered from painful and debilitating injuries, including intestinal blockages and a condition known as gastroparesis, or stomach paralysis.

Allegations of Withheld GLP-1 Safety Information

Former users of Ozempic, Wegovy, Mounjaro, and other GLP-1 RA drugs claim that the manufacturers withheld critical safety information and side effect warnings to prioritize profits over patient safety. According to product liability lawsuits brought against the makers of Ozempic and other GLP-1 drugs, the way the companies aggressively promoted these medications as safe and effective for weight loss without adequately disclosing the potential risks has led to users experiencing severe and life-altering side effects.

A Question of Adequate Drug Warning Labels

Product liability lawyers involved in the mounting lawsuits over Ozempic, Wegovy, Mounjaro, and other similar medications have submitted position papers detailing their stances on whether the manufacturers of these drugs provided adequate label warnings about the potential drug side effects, particularly the risk of stomach paralysis.

“The labels for GLP-1 RAs have never adequately warned of the drugs’ propensity to impair the ability to digest food or that relentless vomiting requiring hospitalization was a risk,” plaintiffs noted in the position paper. “No GLP-1 RA labels warn of the risk of gastroparesis, a paralysis of the stomach resulting in cessation of digestion. Rather, the labels downplay the severity of gastroparesis symptoms, and omit that they can be a feature of potentially life-threatening digestive impairment.” Furthermore, the plaintiffs argue that the manufacturers failed to warn users that they may need to stay on the drugs for the rest of their lives to avoid regaining weight.

In a separate position paper, the drug makers argued that the label warnings were adequate, even though the labels do not explicitly mention the potential risk of gastroparesis. The manufacturers maintain that each plaintiff bringing a lawsuit over Ozempic or another GLP-1 drug should undergo a specific diagnostic test for gastroparesis before asserting claims of stomach paralysis injuries. Plaintiffs responded by stating that discovery would reveal how much the manufacturers knew about the risk of gastroparesis, demonstrating that they deliberately downplayed these health risks to consumers and the medical community.

The Centralization of GLP-1 Injury Lawsuits

Given the common questions of fact and law raised in the growing litigation, the U.S. Judicial Panel on Multidistrict Litigation centralized all GLP-1 lawsuits before U.S. District Judge Gene E.K. Pratter in the U.S. District Court for the Eastern District of Pennsylvania. This consolidation aims to streamline the litigation process and ensure consistency in the handling of the cases. It is anticipated that tens of thousands of lawsuits may ultimately be included in the federal multidistrict litigation (MDL).

The centralization of the lawsuits allows for more efficient pretrial proceedings, including the exchange of information and evidence between parties, the coordination of depositions and expert testimony, and the potential for settlement negotiations. This consolidation increases the chances of a timely resolution for the plaintiffs.

The Impact on Users and Potential Compensation

Users who have experienced severe side effects, including intestinal blockages and gastroparesis, have faced significant physical and emotional challenges. These conditions can cause chronic pain, discomfort, and a decreased quality of life. Some users have required hospitalization, surgery, and ongoing medical treatment to manage their symptoms.

Pursuing a drug injury lawsuit against the manufacturers of Ozempic or other GLP-1 medications provides an opportunity for users to seek compensation for their injuries, losses, and medical expenses. The outcome of these Ozempic lawsuits may result in financial settlements that can help alleviate the financial burden associated with the alleged adverse health effects.

Thousands of GLP-1 Drug Injury Lawsuits Expected

The lawsuits over Ozempic, Wegovy, Mounjaro, and other GLP-1 RA drugs, of which there are expected to be thousands, highlight the importance of suitable label warnings and the ethical responsibilities of pharmaceutical companies. Former Ozempic users allege that they have suffered severe and life-altering side effects due to the alleged failure of the manufacturers to provide adequate warnings about the potential health risks, including gastroparesis or stomach paralysis. The centralization of the lawsuits over Ozempic and other GLP-1 drugs aims to streamline the litigation process and ensure a fair resolution for the plaintiffs.

Scroll to Top